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List of Abbreviations 
 
 
AMD  Age-related macular degeneration     
ALL  Acute lymphoblastic leukemia 
CML  Chronic myelogenous leukemia  
DHFR  Dihydrofolate reductase 
dsRNA Double-stranded RNA 
dTMP  Deoxythymidine monophosphate 
dTTP  Deoxythymidine triphosphate 
dUMP  Deoxyuridine monophosphate 
EGFR  Epidermal growth factor receptor 
GIST  Gastrointestinal stromal tumor 
MAPK Mitogen activated protein kinase 
mRNA Messenger RNA 
MTA  Multi-targeted antifolate  
NSCLC Non-small cell lung cancer 
nt  Nucleotide 
ORN  Oligoribonucleotide 
PDGFR Platelet-derived growth factor receptor 
RISC  RNA-induced silencing complex 
RNAi  RNA interference 
RTK  Receptor tyrosine kinase 
RT-PCR Reverse-transcriptase PCR 
siRNA  Small-interfering RNA 
TKI  Tyrosine kinase inhibitor 
TS  Thymidylate synthase 
VEGF  Vascular endothelial growth factor 
VEGF-R Vascular endothelial growth factor receptor 






The therapeutic potential of a novel multi-targeted small-interfering RNA (siRNA) was 
investigated in human breast cancer cells. Previous studies had identified an siRNA that 
specifically and potently inhibited expression of thymidylate synthase (TS) by directly 
targeting human TS mRNA. TS is a folate-dependent enzyme that catalyzes the key 
reaction involved in synthesizing nucleotide precursors for DNA biosynthesis, and as 
such, it plays a critical role in maintaining cell growth. The goal of this thesis was to 
design and develop a novel siRNA molecule that targeted TS mRNA as well as a cellular 
mRNA that encodes a different cellular protein involved in cancer cell growth and 
proliferation, such as a member of the ErbB family. Gene sequence analysis was 
performed and identified an overlapping sequence between TS and ErbB2 mRNAs.  An 
siRNA duplex was then designed to simultaneously target human TS and ErbB2 mRNA. 
Transfection of the multi-targeted siRNA (TS1M17) revealed that both ErbB2 and TS 
proteins were significantly suppressed in a time and dose-dependent manner in ErbB2-
overexpressing human breast cancer SKBR3 cells. The corresponding mRNA levels, as 
determined by RT-PCR, were also decreased. Protein levels of other ErbB family 
members, including ErbB1 and ErbB3, remained unchanged with siRNA treatment. An 
ErbB2-specific siRNA (B2450) inhibited ErbB2, but had no effect on TS expression 
demonstrating the specificity of the multi-targeted siRNA against both TS and ErbB2. 
Mismatched (TS1-Mismatch) and control (GL2) siRNAs had no inhibitory effects on 
expression of the two target proteins. Suppression of activated ErbB2, as determined by 
expression of phosphorylated ErbB2 protein, was observed with transfection of TS1M17 
siRNA. In addition, the expression of downstream signaling proteins, such as 
phosphorylated mitogen activated protein kinase (p-MAPK), p27Kip1, p21Cip1, cyclin D1, 
and survivin were significantly changed. In contrast, control siRNAs did not exert any 
inhibitory effects on downstream signaling. Taken together, these findings suggest that 
TS1M17 siRNA inhibits signaling of the ErbB2 pathway. The effect of TS1M17 siRNA 
on cytotoxicity was analyzed by WST-1 assay. Upon transfection into SKBR3 cells, the 
TS1M17 siRNA significantly suppressed cell proliferation with an IC50 value of 0.65 nM, 
which is 154-fold more potent than ErbB2- and TS-specific siRNAs. This study suggests 
that targeting expression of ErbB2 and TS, two key proteins involved in distinct and 
critical pathways for cancer growth and proliferation, with a single siRNA molecule may 
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Cancer is the second leading cause of death in the United States. The American Cancer 
Society recently reported 1,400,000 new cases of cancer and 570,000 cancer-related 
deaths in 2006. With recent improvements in public awareness, screening and detection, 
the rate of cancer deaths has been trending down since the 1990’s. Another major 
contribution to reducing cancer-related deaths has been the development of new cytotoxic 
and biologic agents (1). Clinical progress in chemotherapy has been fueled by our 
enhanced understanding of the molecular and genetic basis for cancer and cancer biology. 
Significant efforts have focused on characterizing key signaling networks that regulate 
cellular activities involved in cellular survival, invasion/metastasis, and angiogenesis. 
Many of these networks are found to be radically altered or upregulated in neoplastic 
cells versus normal host tissues. By the early 1990’s, research developing effective agents 
that specifically target defective signaling pathways in cancer cells led to the era of 
“targeted therapy” in oncology (2). These new targets include growth factor receptor 
pathways, modulators of the cell-cycle, proteins involved in apoptosis, and signaling 
molecules responsible for angiogenesis.  
 
Despite the recent successes in cancer drug development, there remain a number of 
serious limitations. First, cancer is a heterogeneous disease. Second, despite their 
specificity, targeted therapies still show toxic side effects that limit their potential clinical 
use. Finally, the well-studied phenomenon of acute and chronic development of 
resistance persists. Therefore, understanding the molecular features of human tumors, 
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improving the overall safety profile, and elucidating the mechanisms of cellular drug 
resistance continue to be key aspects of cancer research. Such efforts are essential as we 
continue the effort to improve cancer-related morbidity and mortality.  
 
Thymidylate Synthase as a Chemotherapeutic Target 
Thymidylate synthase (TS) is a folate-dependent enzyme that catalyzes the reductive 
methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate 
(dTMP) (Figure 1). Once synthesized, dTMP is metabolized intracellularly into 
deoxythymidine triphosphate (dTTP), which is a key nucleotide for DNA replication and 
repair (3). Although these DNA precursors can be formed through the salvage pathway, a 
mechanism catalyzed by thymidine kinase, the reaction catalyzed by TS provides the 
only intracellular de novo source of dTMP. Inhibition of this reaction results in 
immediate blockade of cellular proliferation and growth. Given the central role that TS 
plays in cellular proliferation, TS has been an attractive target for cancer chemotherapy 
(4). 
 
In 1957, the synthesis of 5-fluorouracil (5-FU) was first reported by Heidelberger et al. 
based on the finding that rat hepatoma cells utilized uracil more efficiently than normal 
tissue cells (5). Research at that time led to the development of novel fluoropyrimidine 
compounds which targeted essential biosynthetic processes involved in the growth and 
proliferation of cancer cells (6). 5-FU exerts its anticancer effects through various 
mechanisms, including inhibition of thymidylate synthase (TS), incorporation of 5-FU 
metabolites into DNA, and incorporation of 5-FU metabolites into RNA. While the 
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precise molecular mechanism remains unclear, there is now a large body of evidence 
supporting the view that inhibition of TS is a necessary prerequisite for cancer cell death. 
For the last 50 years, the fluoropyrimidines, and in particular 5-fluorouracil (5-FU), have 
become the backbone of treatment for a wide range of human malignancies, including 





























There are two major classes of drugs targeting TS: fluoropyrimidines, which include 5-
FU and the oral prodrug capecitabine, and the antifolate TS inhibitors, raltitrexed, OSI-
7904L, and pemetrexed. Both drug classes play a pivotal role in the treatment of a wide 
range of human solid cancers. In particular, these agents have shown their greatest 
clinical activity in patients with colorectal cancer (8). However, as with all 
chemotherapeutic regimens, mechanisms of innate and induced drug resistance continue 
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to limit their clinical use. Several studies have documented a strong correlation between 
increased TS enzyme levels and resistance to fluoropyrimidines. Innate resistance to 
fluoropyrimidines has also been observed in patients with breast and colon cancer whose 
tumors express high basal levels of TS. These patients have subsequently been shown to 
be less responsive to 5-FU therapy (9-11). 
 
The molecular pathways involved in the development of acquired drug resistance are 
complex and their understanding provides a foundation to improve current 
chemotherapeutic regimens. There are now known to be different intracellular 
mechanisms involved in the development of resistance in chronic and acute drug 
exposure. In both settings it has been noted that exposure to 5-FU results in an increase in 
TS enzyme level (12,13). It has been hypothesized that the induction of TS protein is a 
mechanism for acquired resistance to fluoropyrimidines (12,14). The cellular events that 
can be altered to induce protein are found at all levels of cellular regulation from gene 
amplification to post-translational modifications. Studies have shown that cancer cells 
under continuous exposure to 5-FU treatment have increased level of protein secondary 
to amplification of the TS gene and increased transcription (15,16). Given the processes 
of gene amplification, transcription and post-transcription require a cascade of 
intracellular pathways, it is logical that these mechanisms leading to increased protein 
expression would require more time and only be seen in the setting of long-term drug 
exposure. Exposure to fluoropyrimidines in in vitro and clinical model systems, results in 
a rapid induction of TS enzyme level (17,18). The prompt increase in TS enzyme level 
must rely on cellular processes that do not require time-consuming intracellular signaling. 
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The acute induction of TS must therefore be modulated by immediate changes in mRNA 
translation and/or protein modifications. A complete understanding of the regulatory 
elements involved in the acute induction of TS after exposure to chemotherapy would 
provide a rational basis to study therapeutic strategies for patients with 5-FU resistant 
tumors and prevent further development of resistance. 
   
Studies noting the importance of translational regulation in drug-mediated TS protein 
induction were conducted by Chu et al., who showed that short term treatment of human 
colon cancer cells with 5-FU resulted in acute increases in both TS enzyme activity and 
protein expression that were not associated with a corresponding change in TS mRNA 
levels (19). Given the regulation of TS expression after exposure to TS-inhibitors seemed 
to be partly regulated by translational control, the regulation of TS mRNA was further 
elucidated. Subsequent work showed that, in addition to its catalytic activity, TS is an 
RNA binding protein that negatively regulates translation of TS mRNA (20-22). The first 
site of binding is located within a region containing the translational start site, and the 
second site is contained within nucleotides 434 to 634 in the protein-coding region of TS 
mRNA. RNA binding studies revealed that TS binds maximally to its own TS mRNA 
when it is in a ligand-free state, resulting in complete translational repression of TS 
mRNA. Further studies demonstrated that when TS protein is bound to its physiological 
substrate, an antifolate substrate, or by the 5-FU metabolite, FdUMP, TS is unable to bind 
to its own mRNA and suppress its own mRNA translation, thereby leading to increased 
synthesis of TS protein. The current working model for translational autoregulatory 
control of TS mRNA is presented in figure 2. The binding of TS to its own mRNA is an 
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efficient mechanism for regulating intracellular levels of TS. This process allows the cell 
to respond rapidly to cytotoxic exposure and ensure the desired level of TS protein for 
cell growth and proliferation. This mechanism provides a rational explanation for the 
acute induction of TS protein seen in cancer cells upon drug exposure and a possible 
etiology for the rapid development of drug resistance (16,23).   
 
AUG
TS mRNA 5’ 3’
UAG
1                              480      550                     1524
dUMP, FdUMP
CH2 FH4, antifolate





Translation             Translation
 
Figure 2. Model of TS translational autoregulation. 
 
 
Given the current understanding of TS translational regulation as outlined above, 
alternative strategies have been developed to target TS expression. One approach would 
include developing small molecules that inhibit TS enzyme activity but do not affect 
binding activity to TS mRNA, thereby circumventing translational induction of TS 
protein. Another approach would be to develop molecules that directly target sequences 
on TS mRNA, resulting in translational inhibition and/or RNA degradation. Such an 
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approach would include the use of small molecules, antisense oligoribonucleotides 
(ORNs), ribozyme-based molecules or short interfering RNAs (siRNAs) that directly 
target TS mRNA. Studies by Schmitz et al. showed that treatment of human colon cancer 
cells with 30-nt 2’-O-methyl antisense ORNs, targeting the 5’-upstream cis-acting 
element of TS mRNA, specifically inhibited TS expression in a time and dose-dependent 
manner (24). They found that antisense ORNs did not affect TS mRNA or the half-life of 
TS protein, suggesting that the mechanism of action of antisense ORNs was by 
translational arrest. Most importantly, the therapeutic potential of antisense ORNs was 
also studied. Preliminary cytotoxicity experiments showed that the 30-nt antisense ORN 
inhibited proliferation of human colon cancer RKO cells with an IC50 value of 200 nM. 
However, upon further testing, it was noted that control ORNs, including sense and 
mismatched sequences, also achieved IC50 values in the submicromolar range. Despite 
their effects on cell toxicity, these controls did not affect TS protein expression. 
Therefore, the cytotoxic effects of the 30-nt antisense ORN could not be fully attributed 
to TS protein inhibition. These nonspecific effects limited their potential use as 
therapeutic agents and led to additional research developing other potential molecules, 
such as TS-specific siRNAs.  
 
RNA Interference  
 
RNA interference (RNAi) is a recently discovered, gene-silencing process in which 
sequence-specific, double-stranded RNA (dsRNA) promotes the degradation of cellular 
mRNA encoded by targeted genes. This evolutionarily conserved process of gene 
silencing is now known to exist in a host of eukaryotic organisms. Although its biological 
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functions are still being elucidated, it is thought to be a regulatory adaptation of cells to 
mount specific attacks against invading nucleic-acid sequences such as those seen in viral 
infections as well as a mechanism of genomic protection from transposon insertion and 
translocation (25,26).  
 
The discovery of RNAi was made when Fire et al. observed that gene silencing could be 
triggered in the nematode Caenorhabditis elegans by injection or feeding of dsRNA (27). 
In this system, silencing is systemic and spreads throughout the entire organism and in 
addition can be transmitted to their progeny. Their studies also showed that dsRNA was 
ten-fold more potent than either sense or antisense single strands alone as silencing 
triggers. The molecular process of RNAi is a simple mechanism in which long dsRNA is 
processed into siRNA of 21-25 nucleotides (nts) in length by a intracellular dsRNA-
specific endonuclease known as Dicer and is depicted in figure 3. These siRNAs are then 
incorporated into a nuclease complex known as RNA-induced silencing complex (RISC). 
Finally, the RISC-siRNA complex becomes activated and is guided to its homologous 
target mRNA by Watson-Crick base pairing for cleavage and degradation by cellular 
nucleases (25).  
 
At the time of its initial discovery, this potent mechanism of post-transcriptional gene 
silencing was limited to basic science research as an ideal functional approach to study 
specific genetic pathways in animal models such as C. elegans and Drosophila. Using 
RNAi in mammalian cells was initially of restricted use secondary to nonspecific 
responses of cells to long dsRNAs. This was until Elbashir and colleagues showed that 
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introduction of synthetic 21-nucleotide siRNA duplexes into mammalian cell lines could 
effectively suppress expression of endogenous genes without initiating nonspecific gene 
silencing pathways (28). Presently, RNAi has played a fundamental role in changing 
biological research and has unveiled a novel tool for human genomic study and further 
















Figure 3. Model of RNA interference. 
 
 
Harnessing RNAi has also extended into the realm of clinical medicine secondary to its 
enormous therapeutic potential. In an era where molecular etiologies of diseases are 
constantly being discovered, developing the use of siRNAs as inhibitors of disease-
causing genes is an obvious application. Studies have already begun to explore the use of 
RNAi as a therapy for diseases such as hepatitis C and B, human immunodeficiency virus 
(HIV) infection, and age-related macular degeneration (AMD) (30-33). However, there 
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are several obstacles that must be overcome before siRNAs move from the laboratory 
bench to the clinic. An obvious limitation of using RNAi is its rapid susceptibility to 
nuclease degradation. Cellular uptake is also an issue, given siRNAs are negatively 
charged molecules that require a cationic transport system to efficiently be taken into 
cells. Another concern with cellular introduction of siRNAs is the potential nonspecific 
effects. The design of efficient siRNAs is an empirical process, given that the precise 
molecular mechanisms of RNAi are not fully understood. Different siRNAs show 
different levels of inhibition, and in practice, only some are effective in gene silencing 
(34). Many studies have shown that siRNAs with base-pair mismatches at specific 
locations on the 21-nucleotide duplexes can still bind to targeted mRNA and efficiently 
initiate target degradation. In fact, it has been shown that guanine (G): uracil (U) base 
pair mismatches, also known as “wobble mutations” are viable in RNA:RNA binding, 
and in particular siRNA:mRNA binding (34,35). In addition, studies have shown that 
base pairing between adenine (A) and cytosine (C) are also well tolerated in siRNA 
binding (36). Furthermore, studies have demonstrated that siRNAs with as few as 7 
complimentary nts to the mRNA target can induce gene silencing. Given this flexibility, 
introduction of siRNAs can target unintended genes that share minimal homology to the 
desired targeted sequence. Of note, possible nonspecific siRNA effects may also arise 
from unintended induction of natural cellular defense mechanisms. Although it was 
initially thought that the small sized siRNA would bypass the immune system, recent 
studies have documented induction of interferon-α (IFN-α) and interleukin-6 (IL-6) in 
mouse serum when lipid-encapsulated siRNAs containing the sequences 5’-UGUGU-3’ 
or 5’-GUCCUUCAA-3’ were introduced systemically (37). Nucleoside modification and 
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proper sequence selection are two strategies currently being used to avoid the 
immunostimulatory effects of siRNAs.  
 
Despite its current limitations, much is being learned about harnessing RNAi for clinical 
therapy. In fact, RNAi has already been introduced to the clinic for the treatment of 
AMD. Two siRNA molecules, Sirna-027 and Cand5, are already in phase I clinical trials. 
These siRNAs respectively target vascular endothelial growth factor receptor-1 (VEGFR-
1) and vascular endothelial growth factor (VEGF) mRNA. The VEGF-signaling pathway, 
of which VEGF and VEGFR are two critical proteins, is a key mediator of angiogenesis, 
an important process that mediates the development of wet AMD. Interim data have 
shown a trend towards improvement of vision. If these siRNAs are found to be safe and 
effective, they have the potential to be approved by the FDA by 2008 as the first 
therapeutic siRNAs.  
 
The use of siRNAs would also be a tremendous tool in cancer therapy and expectations 
for the development of new target-specific drugs remains high. Genetic mutations and 
overexpression of tumor-specific oncofusion proteins have been implicated in an 
increasing number of cancers including leukemia, colon and breast carcinomas, and 
melanomas. The specificity of RNAi makes it possible to silence these disease-causing 
mutant alleles or oncogenes without affecting the wild-type alleles, thereby bypassing the 
negative side affects often seen with traditional cytotoxic chemotherapy. Using RNAi to 
target genes such as bcr-abl and Ras, make it a valuable and novel therapeutic option for 
a broad range of human cancers (31-33).  
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Thymidylate Synthase-Targeted siRNA 
 
Following the successful use of ORNs to inhibit TS expression by Schmitz and 
colleagues, further work was conducted to identify additional molecular approaches to 
target TS mRNA that would inhibit translation (24). The discovery of siRNA technology 
provided a direct mechanism for the degradation of TS mRNA and provided a novel 
approach to prevent TS protein expression as well as negative autoregulation of TS 
mRNA by its own protein end-product. Studies proceeded to elucidate the 
chemotherapeutic potential of siRNA in human cancer. By inhibiting protein expression 
at the mRNA level, it would be possible to prevent the development of drug resistance to 
TS-targeted compounds.  
 
Schmitz et al. investigated whether the use of TS-targeted siRNA duplexes in vitro could 
inhibit the expression of TS protein and prevent the previously studied mechanism of 
drug-induced resistance (38). An siRNA targeting a region on human TS mRNA 
corresponding to nucleotides 1058 to 1077 was designed and transfected into the human 
colon cancer RKO cell line. They showed that treatment of cells with TS-targeted siRNA 
(TS7) potently inhibited the expression of both TS mRNA and protein. These studies 
showed that, compared to ORNs, TS7 siRNA had a longer duration of intracellular 
effects, a greater affinity to TS mRNA as seen by RNA analysis, and a 500- fold increase 
in biological activity. Significant potential therapeutic applications were also suggested 
from these in vitro pre-clinical studies. Schmitz et al. showed that treatment with TS7 
siRNA completely prevented TS protein induction following exposure to TS inhibitors, 
decreasing the development of cellular drug resistance. In addition, TS7 restored 
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chemosensitivity to cells overexpressing TS protein and resistant to various TS inhibitors. 
These studies showed that siRNAs effectively and specifically induced the process of 
RNAi in human colon cancer cells. More importantly, these studies identified a potent 
therapeutic application of siRNAs as single agents and in combination with TS inhibitors 
to overcome the development of cellular drug resistance. This work provided new 
insights towards the development of siRNAs as novel therapeutic molecules directed at 
key cellular pathways involved in cancer growth, proliferation, and survival. 
 
 
Multi-Targeted Cancer Drug Development 
 
Chemotherapeutic drugs have traditionally been developed to target one specific 
pathway. Combination chemotherapy has been a mainstay of cancer treatment since the 
recognition of its beneficial effect for childhood acute lymphoblastic leukemia (ALL) in 
the 1970’s (2). This approach continues to be the cornerstone of therapeutic regimens for 
virtually all cancers, including breast and colorectal tumors. The benefit of combination 
therapy is due to the lower clinical efficacy seen with the use of one drug in the treatment 
of these cancers as well as the prevention of drug-resistance. The novel approach of 
developing molecules that target two or more key pathways in cancer cell growth has 
become more prominent given its beneficial implications in chemotherapy. First, it 
provides increased efficacy against tumor cells. Second, it improves and possibly 
prevents the development of cellular drug resistance to one chemotherapeutic agent. 
Finally, such an approach may simplify patient regimens by targeting multiple pathways 
with a single molecule.  
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Novel multi-targeted inhibitors are currently being designed to specifically target key 
signaling pathways in cancer cell proliferation and metastasis (39). Several of these new 
agents are under clinical investigation (40). A few examples of this class of anti-cancer 
drugs are the tyrosine-kinase inhibitors (TKIs) imatinib, ZD6474, and lapatinib (Table 1). 
Imatinib is a well-established small molecule found to not only target abl, a constitutively 
active kinase in chronic myelogenous leukemia (CML), but also the kinases associated 
with c-kit and platelet derived growth factor (PDGF)-α receptors. This agent is currently 
approved for use by the FDA for CML and gastrointestinal stromal tumors (GIST). 
ZD6474 is a potent inhibitor of VEGFR-2 that also has activity against epidermal growth 
factor receptor (EGFR) and ret (41). Phase I clinical trials showed good therapeutic 
potential in patients with refractory non small cell lung carcinoma (NSCLC) leading to 
phase II trials as first line therapy in NSCLC. Lapatinib, a TKI that targets both EGFR 
and ErbB2, is currently under phase III trials for advanced and refractory breast cancer. 
Recent studies have shown that in combination with capecitabine, lapatinib decreases 
progression of disease without an increase in serious side effects (42,43). Inhibition of the 
EGFR and ErbB2 signaling pathways have resulted in the induction of apoptosis in in 
vitro models of colon carcinoma (44,45). 
 
TS has also been an important focus for multi-targeted treatment given its importance as 
a chemotherapeutic target. Development of the antifolate analog pemetrexed is a prime 
example of a clinically active agent approved by the FDA for the treatment of NSCLC 
and mesothelioma that targets three integral enzymes involved in the synthesis of nucleic 
acids (46). This drug is known as a multi-targeted antifolate (MTA), as it inhibits TS, 
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dihydrofolate reductase (DHFR), and GAR transformylase (GARTF), a key enzyme 
involved in de novo purine biosynthesis (Figure 1).  
 
Table 1. Examples of Multi-Targeted TKIs.  
 























The novel approach to multi-targeted drug design is not necessarily limited to kinase 
inhibitors and antimetabolites. Few studies have successfully implemented the use of 
siRNAs to simultaneously inhibit expression of two proteins. Conceptually, it would be 
possible to transfect several siRNAs into cells targeting a variety of different mRNAs. In 
practice, this has been shown to result in intracellular competition between the siRNAs, 
suggesting that some component of the RISC complex is limiting (47,48). It is 
conceivable that the transfection of multiple siRNA sequences may also increase the 
possibility for a natural immune response. Therefore, the novel technique of using a 
single siRNA molecule to target multiple pathways involved in cancer progression is an 
innovative approach to cancer drug development. 
 
Another group of critical proteins involved in cancer growth and proliferation are the 
ErbB family. These proteins play a pivotal role in the proliferation of many human 
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cancers. Within this family, EGFR and ErbB2 are of particular interest in the study of 
tumor biology given their overexpression in a broad range of solid epithelial tumors 
including colon and breast (49). 
 
 
ErbB Family  
 
The ErbB family is among the best studied growth factor receptor systems since their 
implication in cancer development in the 1980’s, when the avian erythroblastosis tumor 
virus was found to encode a mutated form of the human epidermal growth factor receptor 
(EGFR) (49). The ErbB family is a group of receptor tyrosine kinases (RTKs) whose 
members are membrane spanning proteins expressed in cells of mesenchymal and 
ectodermal origin and normally involved in mediation of human organogenesis and cell-
cell interaction during adulthood (50). It consists of four members: EGFR 
(HER1/ErbB1), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4). All members of 
the ErbB protein family are composed of an extracellular ligand-binding domain, a 
transmembrane region, and an intracellular tyrosine kinase domain. The kinase activity of 
the ErbB family is activated through ligand-induced receptor homo- and 
heterodimerization which triggers autophosphorylation of tyrosine residues in the 
cytoplasmic tail. This in turn can result in a complex and diverse network of protein 
activation involved in the regulation of cell proliferation, differentiation, and survival. 
Two signaling pathways downstream of most active ErbB dimers are the mitogen-
activated protein kinase (MAPK) pathway, and the PI(3)K-activated Akt pathway which 
are both essential pathways in cancer growth (Figure 4) (51). 
 
 




























Fig 4. ErbB signaling network.  
 
 
ErbB2 is a ligand-free receptor and is the preferred dimerization partner for all the other 
ErbB members, including EGFR (52). ErbB2-containing heterodimers have prolonged 
and enhanced downstream signaling when compared to homodimers of the same 
receptors. Moreover, ErbB2 serves as a critical component of breast carcinoma cell 
invasion when coupled to other ErbB receptors (53). Clinically, the pivotal role of ErbB2 
in breast has been well-established as 15-25% of these tumors are known to overexpress 
the ErbB2 receptor (54). In addition, tumors that have varying alterations in ErbB 
receptors generally demonstrate more aggressive disease and poorer clinical outcome (54, 
55).   
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The role of ErbB2 in breast cancer has been discussed above. Although rarely 
overexpressed in colorectal cancer, studies have shown constitutive expression of both 
ErbB2 and EGFR in colon cancer cell lines (56). Evidence suggests that hyperactivation 
of ErbB2 receptors at normal expression levels in colon cancer cells is due to elevated 
levels of growth factor ligands, such as TGF-α and heregulin, produced by the tumors 
themselves (57). This finding indicates that despite normal levels of ErbB2 receptor, 
ErbB2 and its associated dimerization partners (EGFR, ErbB3, ErbB4) could provide the 
signaling basis for tumor growth in cancers that do not overexpress ErbB2, such as 
colorectal, lung, and a majority of breast cancers (58). There is now strong evidence to 
show that the cooperation between these receptors is integral to the oncogenic 
transformation of several human cancers as opposed to the discrete function of the 
individual receptors. 
 
The treatment of various solid tumors with molecules targeting ErbB receptors has gained 
recent validity in the clinic (49,59,60). There are currently two major classes of anti-ErbB 
therapeutic agents. The first includes monoclonal antibodies binding to the extracellular 
domain of the ErbB receptors. Within this group are trastuzumab, an ErbB2-targeted 
monoclonal antibody and cetuximab and panitumumab, two EGFR-targeted antibodies. 
Trastuzumab is presently approved for the treatment of ErbB2-overexpressing breast 
cancer, while cetuximab and panitumumab are approved for advanced/metastatic 
colorectal cancer (61-63). The second class of anti-ErbB agents are small-molecule 
tyrosine-kinase inhibitors (TKIs). These molecules compete with ATP in the ATP 
binding pocket of the tyrosine-kinase domain of the receptor and have taken center stage 
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in modern molecular cancer treatment (64,65). Erlotinib and gefitinib are molecules that 
target EGFR and these agents are approved for the treatment of NSCLC. Lapatinib is a 
dual inhibitor that targets both EGFR and ErbB2, and the expectation is this novel 
molecule will soon be approved by the FDA for the treatment of advanced breast cancer. 
Although these agents show significant promise, the development of cellular drug 
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Statement of Purpose 
 
 
For this research project, I hypothesize that siRNAs can be designed and developed to 
inhibit the expression of multiple key proteins involved in cancer cell growth and 
proliferation. Given the central role of TS in cellular proliferation, I set out to design a 
TS-targeted siRNA that targets TS as well as other critical proteins implicated in the 
growth of human cancers. Both TS and EGFR are important targets of current 
chemotherapeutic agents used for colorectal cancer, and as such, sequence analysis was 
performed in search of an overlapping sequence between TS and EGFR mRNAs. 
However, no homologous sequences could be identified. With the understanding that 
ErbB family members function primarily as heterodimers and that targeting other ErbB 
receptors may lead to similar downstream effects on colon cancer cell proliferation, the 
search was extended to other ErbB family members. A comparison between TS and 
ErbB2 mRNAs revealed a 19-nt sequence with 80% base-pair homology. ErbB2 mRNA 
encodes an important growth factor receptor that is critical for the growth and 
proliferation of breast cancers as well as other solid tumors. In addition, TS is an 
important target for current breast cancer therapy. Taking advantage of the innate 
flexibility of designing siRNAs, an siRNA that simultaneously targets human ErbB2 and 
TS mRNA was developed.   
 
The main goal of my project is to investigate the therapeutic application of multi-targeted 
siRNAs. To achieve this goal, my research project has 3 main aims, and they are as 
follows: 
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Aim 1: Characterize the molecular mechanisms by which multi-targeted siRNAs 
control and suppress the expression of ErbB2 and TS protein using human breast cancer 
cells as my in vitro model system 
 
Aim 2: Optimize the in vitro effects of multi-targeted siRNAs  
 
Aim 3: Investigate the in vitro cytotoxic effects of multi-targeted siRNAs  
  
   - 27 - 
Materials and Methods 
 
 
siRNA Synthesis. siRNA duplexes were designed to simultaneously target sequences on 
human TS mRNA corresponding to nucleotides 2-20 (5’-
CCACUUGGCCUGCCUCCGU-3’) and human ErbB2 mRNA corresponding to nts 903-
921 (5’-CUGCCUGGCCUGCCUCCAC-3’). A series of siRNAs with base pair 
mismatches to these targets were additionally designed. The selected sequences were 
screened in a BLAST search against all known human genes to verify that no other genes 
were targeted. siRNA duplexes were obtained from Dharmacon Research (Lafayette, 
CO). In addition, an siRNA duplex previously studied by Schmitz et al. (38) targeting a 
non-homologous region of TS corresponding to nts 1058-1077, an siRNA duplex 
targeting ErbB2 corresponding to nts 2450-2469, and a control siRNA duplex GL2, were 
obtained from Dharmacon. All siRNA’s contained two symmetric 3’ overhangs of two 
2’-deoxythymydine nts.  
 
Cell Culture. Human breast cancer cell lines SKBR3 and MCF-7 were obtained from the 
American Type Culture Collection (Manassas, VA). All cells were maintained in 75-cm2 
tissue flasks (BD Bioscience; San Jose, CA) in a 100% humidified incubator at 37°C. 
Cells were grown continuously in growth medium containing RPMI-1640 (Invitrogen; 
Carlsbad, CA) with 10% dialyzed fetal bovine serum (Invitrogen). Baseline growth 
experiments were performed to determine the doubling time of the human breast cancer 
cell lines. SKBR3 and MCF-7 cells were found to have doubling times of 40 and 57 hrs, 
respectively.  
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siRNA Transfection. SKBR3 cells were plated in 25-cm2 flasks in 3 ml of RPMI-1640 
at a density of 5 x 105 cells per flask. siRNA duplexes were complexed with the cationic 
lipid Lipofectamine (Invitrogen) in OPTI-MEM medium as described by the 
manufacturer’s protocol. Briefly, 2 µl of Lipofectamine were diluted in 148 µl of OPTI-
MEM medium and allowed to sit at room temperature for 5 min. Diluted Lipofectamine 
was added to diluted siRNA of desired concentration and incubated for 20 min at room 
temperature. Total aliquots of 300 µl were added to the 25-cm2 flasks under sterile 
conditions. At 48 hrs post-transfection, SKBR3 cells were deprived of growth serum by 
incubating in non-supplemented medium for 24 hours. This change in medium conditions 
was sufficient to induce protein phosphorylation. Cells were washed twice with ice-cold 
PBS and either trypsinized or detached with a rubber policeman. 
 
For cell proliferation assays, SKBR3 and MCF-7 cells were plated in 96-well tissue 
culture plates (BD Bioscience) in 100 µl of RPMI-1640 at a density of 4 x 104 and 2.5 x 
104 cells/well, respectively. For cytotoxicity experiments, the cationic lipid 
Oligofectamine (Invitrogen) was used. Oligofectamine (0.4 µl, 0.6 µl) was added to 
OPTI-MEM medium for a total volume of 15 µl and allowed to sit for 5 min at room 
temperature. This dilution was combined with 35 µl of diluted siRNA and incubated for 
15 min before addition to individual wells.     
 
Western Immunoblot Analysis. SKBR3 cells were plated, transfected, and harvested as 
described above. Cell pellets were resuspended in RIPA cell lysis buffer [10 mM Tris 
(pH 7.4), 150 mM NaCl, 1% Igepal (Sigma-Aldrich Co., Milwaukee, WI), 0.5% 
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deoxycholic acid and 1% SDS] containing freshly added phenylmethylsulfonyl fluoride 
and protease inhibitor mixture (Sigma; St. Louis, MO). Phosphorylated proteins were 
extracted by resuspension of cell pellets in PhosphoSafe Extraction Buffer (Novagen; 
Darmstadt, Germany) along with the protease inhibitor mixture. Suspensions were 
incubated on ice for 20 min and then centrifuged at 14,000 rpm for 10 min at 4°C. Protein 
concentrations of the supernatant were determined using the DC protein assay (Bio-Rad; 
Hercules, CA). Equivalent amounts of protein (10-70 µg) from each cell lysate were 
resolved on SDS-PAGE (7.5-12.5% acrylamide) and electroblotted onto a nitrocellulose 
membrane (0.45 µm filter; Bio-Rad). Membranes were incubated in blocking solution (1 
x PBS or 1 x TBS, 0.1% Tween-20, and 5% nonfat dry milk powder) for 1 hour at room 
temperature. Membranes were incubated with primary antibodies overnight at 4°C in 5% 
TBST, 5% PBST or 5% bovine serum albumin. The following antibody dilutions were 
used:  TS, 1:2,000 (Zymed Lab.; 4H4B1); EGFR, 1:500 (BD Trans. Labs; 555996); 
ErbB-2, 1:2,500 (Oncogene; Ab-3); phospho-ErbB2, 1:1,000 (Neomarkers; Ab-18); 
ErbB3, 1:500 (Neomarkers; Ab-2); phospho-MAPK, 1:500 (Santa Cruz Biotechnology; 
sc-7383); α-tubulin, 1:2,500 (Santa Cruz; sc-8035); cyclin D1, 1:500 (Santa Cruz; sc-
20044); p21, 1:500 (Cell Signaling); p27, 1:500 (Calbiochem; Ab-2) and survivin 1:1,000 
(Cell Signaling; 2802). The polyclonal MAPK protein (sc-94) antibody was purchased 
from Santa Cruz (Santa Cruz, CA) and used at a dilution of 1:1,000. The anti-
topoisomerase I monoclonal antibody was a gift from Dr. Yung-chi Cheng, Yale 
University, New Haven, CT and used at a dilution of 1:2000. After five 10 min washes, 
membranes were incubated with a 1:2,000 dilution of horseradish peroxidase-conjugated 
secondary antibody (IgG goat antimouse/IgG goat antirabbit; Bio-Rad) for 1 hr at room 
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temperature. This was followed by five additional 10 min washes. Membranes were then 
processed by the enhanced chemiluminescence method (SuperSignal West Pico substrate; 
Pierce, Rockford, IL), and protein bands were visualized by autoradiography. 
Quantitation of signal intensities was performed using densitrometry on a Hewlett-
Packard ScanJet 5370C (Palo Alto, CA) with NIH image 1.62 software.  
 
Reverse Transcriptase PCR. SKBR3 cells were plated and transfected in 25-cm2 flasks 
as described. Total RNA was purified 72 hours after transfection using the RNeasy Mini 
Kit (Qiagen; Valencia, CA) as described by the manufacturer’s protocol. RNA 
concentration was then determined and verified by running 1% agarose/formaldehyde 
gels. cDNA was synthesized from 1 µg of total RNA using the ThermoScript RT-PCR 
System (Invitrogen) and amplified by PCR using Taq DNA polymerase (Qiagen). The 
primers used for PCR amplification are as follows: 
 
ErbB2 (484 bp):  (F) 5’-GAGATCTTGAAAGGAGGGGTCT-3’ 
(R) 5’-CGTCCGTAGAAAGGTAGTTGTAGG-3’ 
EGFR (550 bp): (F) 5’-AGAGGAGAACTGCCAGAAACTG-3’  
(R) 5’-AGGAGGAGTATGTGTGAAGGAGTC-3’ 
ErbB3 (499 bp): (F) 5’-GTGGATGGCCCTTGAGAGTA-3’ 
(R) 5’-ACGTGGCCGATTAAGTGTTC-3’ (67) 
TS (440 bp):  (F) 5’-GGGCAGATCCAACACATCCT-3’ 
(R) 5’-CAAGCGCACATGATGATT-3’ 
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 440 bp) specific PCR products 
using (F) 5’-TCATCTCTGCCCCCTCTGCT-3’ and (R) 5’-
CGACGCCTGCTTCACCACCT-3’ primers from the same samples were amplified and 
served as internal controls, where F and R are the forward and reverse primers, 
respectively. Each amplification cycle consisted of 30 seconds at 95°C for denaturation, 
30 seconds at 55°C for primer annealing, and 1 minute at 72°C for extension. After 
amplification, DNA products were analyzed by 1% agarose gel electrophoresis.  
 
Cell Growth Assay. Growth inhibition and cell toxicity was evaluated by WST-1 assay 
(Roche Applied Science; Indianapolis, IN). In this assay, quantification of cell 
proliferation and cell viability is based on the cleavage of the tetrazolium salt WST-1 by 
mitochondrial dehydrogenases in viable cells. In brief, SKBR3 and MCF-7 cells were 
seeded in 96-well tissue culture plates, as described above. At 24 hours after seeding, 
cells were treated with siRNA:Oligofectamine complexes. A volume of 15 µl of WST-1, 
equaling 10% of the total well volume, was added to each well of SKBR3 and MCF-7 
plates after 7 and 6 days of siRNA exposure, respectively. Reactions were incubated at 
37°C for 1 hr. Absorbance at 630 nm was recorded using a 96-well plate reader. All 















Inhibition of ErbB2 and TS protein expression by a multi-targetd siRNA in SKBR3 
cells. Previous studies by Schmitz et al. have shown that thymidylate synthase (TS)-
targeted siRNAs effectively and specifically induced the process of RNAi in human 
colon cancer cells (38). siRNAs were able to inhibit TS expression in the low nanomolar 
range, suggesting the potent therapeutic potential of siRNAs. I subsequently investigated 
the ability of a single siRNA duplex to simultaneously inhibit expression of TS and 
another key cellular protein involved in cancer cell growth and proliferation, namely the 
ErbB2 growth factor receptor. Sequencing analysis identified a 19-nt sequence on TS 
mRNA (nt 2 -20) that had 15-nt homology to nt 903-921 on ErbB2 mRNA (Figure 5A). 
Of note, the ErbB2 mRNA encodes an important growth factor receptor that is critical for 
the growth of breast cancer as well as other solid tumors. An siRNA duplex, TS1, was 
designed to be complementary to this region on human TS mRNA. Preliminary studies 
using the human colon cancer RKO cell line showed that transfection with the TS1 
siRNA markedly reduced expression of both ErbB2 and TS protein (data not shown). 
However, the decrease in ErbB2 protein expression was not as significant as that seen 
with an siRNA molecule designed to specifically target ErbB2, B2450 (data not shown). 
 
To extend these studies to a biological model that would be more responsive to a multi-
targeted siRNA that inhibited both TS and ErbB2, further work was conducted in a 
human breast cancer cell line known to overexpress ErbB2, SKBR3 cells. In an attempt 
to improve potency of TS1 in downregulating expression of ErbB2, siRNAs were 
designed that contained corrected mismatches to ErbB2 mRNA. All positions in this 
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study are reported from the 5’-end of the antisense strand of the siRNA. As seen in figure 
5A, TS1M15 was designed to contain a guanine (G) at the 15th position instead of an 
adenine (A). TS1M17 was designed to contain a cytosine (C) on the 17th position instead 
of a uracil (U). TS1M17M18 had two corrected mismatches on the 17th and 18th 
positions, which in addition to changing a U for a C, changed a G residue to an A at the 
18th position. The effect of these mismatched siRNAs on protein expression was 
investigated by Western blot analysis. Upon transfection into SKBR3 cells at a 
concentration of 10 nM, both TS1M17 and TSM17M18 significantly inhibited ErbB2 and 
TS protein expression (Figure 5B). The siRNA TS1M15 lost its inhibitory effects on both 
ErbB2 and TS protein expression. The expression of two control proteins, α-tubulin and 
topoisomerase-I, was unaffected by siRNA treatment. In addition, treatment with a 
control GL2 siRNA, at a concentration of 10 nM, had no effect on levels of ErbB2, TS, 
or control proteins, suggesting that transfection of the ErbB2/TS siRNAs had specific 
effects on protein expression. Additional experiments suggested that the TS1M17 siRNA 
showed greater inhibitory activity on expression of both ErbB2 and TS proteins than TS1 
or TS1M17M18 (data not shown). Given this observation, I proceeded to focus on 
elucidating the biological effect and therapeutic potential on TS1M17 siRNA.  
 
A time course experiment was then performed to determine the duration of effect of 
TS1M17 siRNA treatment on levels of ErbB2 and TS protein. As seen in figure 6, 
TS1M17 effectively decreased levels of both ErbB2 and TS protein by 48 hours of 




TS mRNA 5’-CCACUUGGCCUGCCUCCGU -3’
siRNA duplex       dTdT- GGUGAACCGGACGGAGGCA 
CCACUUGGCCUGCCUCCGU-dTdT
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Fig. 5. Effect of multi-targeted small interfering RNAs (siRNAs) on ErbB2 and TS protein 
expression in SKBR3 cells. (A) Schematic of TS1 siRNA duplex with targeted region on TS and 
ErbB2 mRNA. Solid lines denote non-homologous base-pairs to the antisense strand of TS1 
siRNA; (B) Western blot analysis of SKBR3 cells after treatment with TS1, mismatched 
(TS1M15, TS1M17, TS1M17M18) and control (GL2) siRNAs. Cells were transfected with 
Lipofectamine alone (untreated) or with 10 nM of TS1, TS1M15, TS1M17, TS1M17M18 and 
GL2 siRNAs for 72 hrs. Cell extracts were processed for Western blot analysis as described in 
“Materials and Methods”.  
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siRNA exposure. The expression of both proteins rapidly decreased to <10% and <5%, 
respectively, following a 24-hr incubation period (Figure 6). By 96-hrs, ErbB2 and TS 
expression had increased and returned to base-line levels by 120-hrs (data not shown), 
demonstrating that maximal protein inhibition occurred at 72-hrs of siRNA exposure in 
SKBR3 cells. The expression of α-tubulin remained unaffected over this same time 
course. Given this data, all subsequent siRNA transfection experiments were performed 




















Fig. 6. Duration of effect of TS1M17 siRNA on expression of ErbB2 and TS protein in SKBR3 
cells. SKBR3 cells were transfected with 10 nM of TS1M17 siRNA and harvested prior to 
transfection (untreated) and at the following times: 24, 48 and 72 hrs. Cell extracts were 
processed for Western Blot analysis as described in “Materials and Methods”.  
 
 
A dose-dependent experiment was subsequently performed using varying concentrations 
of the siRNA in order to identify the range of concentration in which TS1M17 siRNA 
was able to coordinately inhibit the expression of ErbB2 and TS protein in SKBR3 cells,. 
As seen in figure 7, TSM17 siRNA inhibited the expression of ErbB2 and TS protein in a 
dose-dependent manner with 50% inhibition observed at 0.1 nM.  Maximal inhibition of 
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ErbB2 (>90%) and TS (>95%) was observed at 72 hrs of 10 nM TSM17 siRNA 
transfection. Of note, inhibition of ErbB2 and TS protein expression was not enhanced 
when SKBR3 cells were treated with higher concentrations of TS1M17 siRNA, up to 100 
nM (data not shown). This difference in protein inhibition suggests that the increased 
levels of ErbB2 protein in SKBR3 cells does not allow for complete inhibition of ErbB2 
by the TS1M17 siRNA. Expression of control proteins, topoisomerase-I and α-tubulin, 
remained unaffected with siRNA treatment. As an important control, treatment with 10 
nM of the control GL2 siRNA also had no effects on levels of ErbB2, TS, or control 
proteins.  
 








Fig. 7.  Dose-dependent effect of TS1M17 siRNA on ErbB2 and TS protein in SKBR3 cells. 
SKBR3 cells were transfected with Lipofectamine alone (0 nM) and varying concentrations (0.01, 
0.1, 1, 10 nM) of TSM17 siRNA for 72 hrs. Cell protein extracts were processed for Western Blot 
analysis as described in “Materials and Methods”.  
 
 
Specific inhibition of ErbB2 and TS expression by TS1M17 siRNA in SKBR3 cells. 
As described above, our results documented the successful implementation of 
simultaneously inhibiting two proteins with one siRNA in an in vitro model. These 
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results suggested a potential therapeutic approach to targeting multiple critical proteins 
involved in tumor cell growth. However, previous studies have shown that siRNAs can 
target unintended genes that share minimal homology to the desired targeted sequence 
(34). I therefore set out to confirm target specificity of the multi-targeted siRNA, 
TS1M17, in SKBR3 cells. To demonstrate that the decrease in ErbB2 and TS were 
secondary to direct RNAi of each target, ErbB2- and TS-specific siRNAs were designed. 
The ErbB2-specific siRNA, B2450, targets a protein coding region (nt 2450-2458) on 
ErbB2 mRNA.  The TS-specific siRNA TS7 was previously studied and shown to 
specifically target the 3’-UTR immediately downstream of the translational stop site (nt 
1058-1077) of TS mRNA (38). Sequences were screened by BLAST search to verify that 
no other genes were targeted. Western blot analysis showed that SKBR3 cells transfected 
with TS1M17 had significant effects on ErbB2 and TS protein (Figure 8A). Based on this 
analysis, B2450 and TS7 siRNAs only inhibited their intended protein targets, ErbB2 and 
TS, respectively (Figure 8A). In addition, transfection with B2450 siRNA demonstrated 
limited silencing ability compared to TS1M17, reducing ErbB2 by only 50% of control. 
The mismatched control siRNA, TS1 Mismatch (TS1-MM), and GL2 control siRNA had 
absolutely no effect on expression of either protein at 10 nM concentrations. In addition, 
the expression of control housekeeping proteins, topoisomerase-I and α-tubulin, remained 
unchanged in response to treatments with any of the siRNAs.  
 
There are 4 members of ErbB family of receptors, and they share variable sequence 
homology. Therefore, experiments to determine effects of TS1M17 siRNA on expression  



































































































Fig. 8. Specificity of effect of TS1M17 siRNA on ErbB2 and TS protein expression in SKBR3 
cells. (A) Western blot analysis of SKBR3 cells after treatment with 10 nM of TS1M17, ErbB2-
specific (B2450), TS-specific (TS7) and control (TS1 Mismatch and GL2) siRNAs; (B) Effect of 
TS1M17 on expression of ErbB1 and ErbB3 in SKBR3 cells. Cells were transfected with 
Lipofectamine alone (untreated) or with 10 nM of TS1M17, TS1 Mismatch (TS1-MM), and GL2 
siRNAs for 72 hrs. Cell extracts were processed for Western blot analysis as described in 
“Materials and Methods”.  
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of other ErbB family members in SKBR3 cells were done. Previous work (68) has shown  
that these cells express ErbB1 and ErbB3 but not ErbB4. Given this finding, Western blot 
analysis confirmed that SKBR3 cells indeed expressed ErbB1 and ErbB3 protein levels. 
Our studies revealed that levels of both ErbB1 and ErbB3 protein remained unaffected 
after transfection with 10 nM of TS1M17 siRNA (Figure 8B). In addition, control, TS1 
Mismatch and GL2, siRNAs had absolutely no affect on expression of either receptor 
protein. As an important control, the levels of topoisomerase-I protein remained 
unchanged under all conditions. 
 
The proposed mechanism of RNAi is post-transcriptional cleavage of target mRNA (25). 
To gain insight into the potential molecular mechanism by which TS1M17 siRNA was 
exerting its effects on ErbB2 and TS protein expression, levels of ErbB2 and TS mRNA 
were verified. Preliminary Northern blot analysis showed decreased expression of ErbB2 
mRNA with TS1M17 siRNA transfection (data not shown). To confirm these results, I 
used RT-PCR analysis to show effects of TS1M17 siRNA on ErbB2 and TS mRNA 
levels. As seen in figure 9, transfection with TS1M17 significantly decreased expression 
of ErbB2 and TS mRNAs to barely detectable levels in SKBR3 cells (<5% of control). 
As two important controls, the TS1 Mismatch and GL2 siRNAs had no effect on levels of 
either mRNA. As another important control, GAPDH mRNA expression remained 
unchanged with siRNA treatment. Although these results are not exactly quantitative, the 
absence of ErbB2 and TS PCR products confirms that TS1M17 siRNA inhibits protein 
expression through degradation of target mRNA and not through translational inhibition. 
These experiments, taken together, lend further support that TS1M17 siRNA successfully 
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Fig.  9.  Effect of TS1M17 siRNA on ErbB2 and TS mRNA in SKBR3 cells. SKBR3 cells 
transfected with Lipofectamine alone (untreated) or 10 nM of TS1M17 and control (TS1 
Mismatch and GL2) siRNAs. Cells were transfected for 72 hrs, and total RNA from cells was 
isolated, reverse-transcribed, and then amplified using gene-specific primers as described in 
“Materials and Methods”. DNA products were resolved on 1% agarose gels and visualized. 




TS1M17 siRNA inhibits ErbB2 phosphorylation and downstream signaling 
molecules in SKBR3 cells. The effects of ErbB2 activation on cytoplasmic signal 
transduction proteins in the Ras/MAP kinase pathway have been well defined (Figure 4). 
Previous studies have shown that inhibition of ErbB2 by monoclonal antibodies or 
receptor tyrosine kinase inhibitors (TKIs) have subsequent effects on phosphorylation of 
ErbB2 as well as downstream phosphorylation of MAPK (69,70). In addition, 
Ras/MAPK and the PI(3)K/Akt signaling have been implicated in the regulation of cell 
cycle modulators p27Kip1, p21Cip1, cyclin D1 and the apoptosis inhibitor, survivin (71,72). 
In contrast to TKIs, which inhibit the tyrosine kinase domain of the growth factor 
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receptors, siRNAs exert their effects at the mRNA level. Although previous experiments 
showed that TS1M17 siRNA effectively inhibited the basal expression of ErbB2, its 
effects on phosphorylated ErbB2 were unknown. The effects of TS1M17 siRNA on 
tyrosine phosphorylation of ErbB2 in SKBR3 cells were studied. As seen in figure 10, 
TS1M17, at a concentration of 10 nM, was capable of inhibiting expression of both the 
unactivated and activated forms of ErbB2 to <5% compared to baseline levels at 72 hrs 
after transfection.  
 
I next examined whether a decrease in ErbB2 phosphorylation levels secondary to 
TS1M17 siRNA transfection, resulted in downstream signaling effects on the ErbB2 
signaling pathway. Western blot analysis revealed that MAPK expression was similar for 
all transfection conditions (Figure 10). However, activated MAPK, as measured by 
phospho-MAPK levels, was reduced by 44% in cells treated with 10 nM of TS1M17 
siRNA for 72 hours. The expression of other key downstream proteins was then 
analyzed. I observed that the same concentration of 10 nM TS1M17 siRNA decreased 
expression of cyclin D1, p21, and survivin to 13, 30, and 15%, respectively, compared to 
baseline protein levels and control transfections with 10 nM of TS1 Mismatch (TS1-MM) 
and GL2. In addition, transfection with TS1M17 siRNA upregulated the expression of 
p27 to 7.3-fold higher than baseline levels (Figure 10). The level of topoisomerase-I 
remained unchanged with each of the conditions, providing an important negative 
control. These results suggest that treatment with TS1M17 siRNA results in inhibition of 
ErbB2 downstream signaling.  
 
 
















































































































































































































































































































Fig. 10. Effect of TS1M17 siRNA on ErbB2 receptor phosphorylation and signaling molecules in 
SKBR3 cells. SKBR3 cells were transfected for 72 hrs with Lipofectamine alone (untreated) or 
10 nM TS1M17 and control (TS1 Mismatch and GL2) siRNAs. Cells were then harvested for 
Western Blot analysis as described in “Material and Methods”. Phosphoprotein levels were 
examined by using anti-pErbB2 (p-Tyr1248) antibody and anti-pMAPK (p-Tyr204) antibody.  
 
 
TS1M17 inhibits cellular proliferation in SKBR3 and MCF7 cells. To determine the 
effect of TS1M17 siRNA on the growth and proliferation of SKBR3 cells, a series of cell 
proliferation experiments was performed. SKBR3 cells were treated with a concentration 
range of 0.01 to 100 nM siRNA for a total of 7 days. Cell growth was marginally 
suppressed by TS7 siRNA, a TS-specific siRNA previously shown to have no effect on 
ErbB2 protein expression, and cell growth was inhibited by only 30%, using a 
concentration of 100 nM (Figure 11A). B2450, the ErbB2-specific siRNA, had a greater 
effect than TS7, resulting in 51% inhibition of cell proliferation at a concentration of 100 
nM. The most significant effect was seen after treatment with the multi-targeted siRNA,  






























































































































Fig. 11.  Effect of ErbB2 and TS siRNAs on cellular proliferation in SKBR3 and MCF-7 cells. 
Cells were transfected with various concentrations of TS1M17, ErbB2-specific (B2450), TS-
specific (TS7), and control (TS1-Mismatch and GL2) siRNAs. Cell proliferation was determined 
by the WST-1 assay as described in “Materials and Methods”. (A) SKBR3 cells were treated for 7 
days; (B) MCF-7 cells were treated for 6 days. Values represent the mean ± SD from 4 to 7 
experiments.  
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TS1M17. Transfection resulted in 78% inhibition with 10 nM of TS1M17 siRNA and an 
IC50.value of 0.65 nM. Higher concentrations of TS1M17 siRNA (up to 100 nM) resulted 
in only slightly higher growth inhibition (82%). This result correlated with our initial 
observation that concentrations greater than 10 nM did not result in improved silencing 
effect on ErbB2 or TS protein expression. This finding also suggested that the increase in 
growth-inhibitory effects of TS1M17 siRNA, although mostly secondary to ErbB2 
protein inhibition, could possibly be accounted for by the additional inhibition of TS 
protein expression. As an important control, TS1 Mismatch had minimal effect on cell 
growth.  
 
Given that SKBR3 cells overexpress ErbB2, cell growth assays were also performed 
using a human breast cancer cell line, MCF-7, which expresses lower baseline levels of 
ErbB2 (68,73). For these experiments, MCF-7 cells were treated with varying 
concentrations (0.01-100 nM) of siRNA for a total of 6 days. The doubling time for the 
cell line was noted to be 17 hrs shorter than SKBR3 cells and therefore required a shorter 
incubation period (data not shown). As seen in figure 11B, TS7 and TS1M17 siRNAs 
inhibited cell proliferation to a similar extent. These findings suggest that the observed 
effect on cell growth in MCF-7 cells is mainly secondary to TS inhibition. The IC50 value 
of TS1M17 siRNA in MCF-7 cells was not calculated given maximum growth inhibition 
was 48%. Although statistically not significant (p≤0.1), at 100 nM concentration, 
TS1M17 had a slightly greater effect on suppression of cellular proliferation than the TS- 
specific siRNA TS7, 48 ± 5.6% and 39 ± 4%, respectively. These findings suggest the 
possibility of enhanced effects secondary to ErbB2 protein inhibition at higher doses. 
Transfection with B2450 and GL2 had absolutely no effect on MCF-7 cell proliferation. 
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Discussion 
 
In this research project, I investigated the therapeutic potential of a novel multi-targeted 
siRNA in human breast cancer cells. Schmitz and colleagues had previously identified an 
siRNA that specifically and potently inhibited expression of TS by targeting TS mRNA 
(38). This and other studies revealed the therapeutic potential of utilizing RNAi as an 
approach to targeted cancer drug development. As previously mentioned, there is a large 
investigational effort to develop drugs that target multiple cellular pathways. Previous 
work transfecting cells with two siRNAs simultaneously, showed that once introduced 
into the cell, siRNAs compete with each other, suggesting that there is a limiting aspect 
to the RNAi machinery (47,48). Given this work, as well as the successes seen with 
multi-targeted drug therapies, an siRNA duplex that targeted TS mRNA as well as a 
cellular mRNA that encodes a different cellular protein involved in cancer cell growth 
and proliferation, such as a member of the ErbB family, was designed and developed. 
Through gene analysis, a 19-nt sequence on human TS mRNA was found that was 80% 
homologous to human ErbB2 mRNA (Figure 5A). In analyzing this multi-targeted 
siRNA, TS1, all five mismatches to ErbB2 mRNA were noted to be G:U or A:C base-
pairs (Figure 5A). Previous RNAi work had shown that both of these mismatches are 
viable base-pairs in siRNA binding, providing support that TS1 siRNA could 
successfully and simultaneously target human ErbB2 and TS mRNAs (35,36). Our 
studies showed that, despite the mismatched base-pairs, there was significant suppression 
of both ErbB2 and TS protein (Figure 5B). As seen in figure 5B, altering one of five 
mismatches on the same siRNA resulted in a significant difference in ErbB2 and TS 
protein expression in SKBR3 cells. By correcting the 15th nucleotide mismatch, TS1M15 
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siRNA lost its effects on ErbB2 and TS protein expression. In contrast, correcting the 17th 
base-pair mismatch showed greater inhibitory activity on both ErbB2 and TS protein 
expression than TS1 siRNA. Taken together, these experiments support previous findings 
reported by Tuschl et al. that the design of effective siRNAs is an empirical process given 
that base-pair mismatches at specific locations in the siRNA duplex can enhance or 
decrease the effect of the siRNA (34). In addition, given the enhanced effect of TS1M17 
siRNA, I proceeded to characterize in greater detail the biological activity of this siRNA.  
 
Studies revealed that transfection of TS1M17 siRNA significantly inhibited expression of 
ErbB2 and TS protein for up to 72 hrs (Figure 6). Previous studies by Schmitz et al. had 
shown that a TS-specific siRNA exhibited a longer inhibitory effect in human colon 
cancer RKO cells (38). These studies showed that inhibition of TS was maximal at 48 hr 
and lasted up to 5 days. The discrepancy between duration of protein repression could be 
explained, at least in part, by the different model system used in each study. The half-life 
of siRNAs in SKBR3 cells may be significantly shorter than the half-life of siRNAs in 
RKO cells. In addition, the overexpression of ErbB2 protein in SKBR3 cells may also 
have direct impact on the effective duration of RNAi of ErbB2 mRNA. As seen in figure 
7, TS1M17 siRNA also inhibited ErbB2 and TS protein expression in a dose-dependent 
manner.  Maximal inhibition of ErbB2 and TS protein, 90% and 95%, respectively, 
occurred at a concentration of 10 nM. Increasing the concentration of TS1M17 siRNA to 
100 nM did not further enhance the inhibitory effects on protein expression in SKBR3 
cells (data not shown). This finding is noteworthy for two reasons. First, despite higher 
concentrations of TS1M17 siRNA, ErbB2 protein levels were not completely suppressed. 
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This finding can be explained by the increased levels of ErbB2 protein expressed in 
SKBR3 cells. Second, treatment with 100 nM concentrations of TS1M17 siRNA did not 
significantly inhibit more cells than 10 nM concentrations (78 and 82%) in SKBR3 cells 
(Figure 11). This correlation strongly supports our underlying hypothesis that the growth 
inhibitory effects of TS1M17 siRNA are secondary to inhibition of protein expression 
caused by RNAi and not secondary to non-specific effects of introducing exogenous 
siRNA to the cells.  
 
As discussed above, the use of a single siRNA molecule to inhibit two proteins was 
successfully implemented in SKBR3 cells. A concern with the use of siRNAs is non-
specific targeting, particularly in light of previous findings that mismatched siRNAs can 
induce inhibition of non-homologous targets (34). To address this concern, a series of 
experiments that would enhance our understanding of the specificity and mechanism of 
ErbB2 and TS protein inhibition by TS1M17 siRNA were performed. To prove 
specificity of target, experiments were designed to show that treatment with TS1M17 
siRNA did not affect other cellular proteins, particularly other members of the ErbB 
family, which have a high level of sequence homology to ErbB2. As seen in figure 8B, 
TS1M17 siRNA did not affect ErbB1 or ErbB3 protein levels. Western blot analysis 
shows that TS1M17 siRNA treated SKBR3 cells express the same levels of protein as 
untreated and treated controls (TS Mismatch and GL2 siRNAs). In addition, other 
cellular proteins remained unaffected. Levels of α-tubulin and topoisomerase-I remained 
unchanged in response to treatments with siRNAs, further reinforcing the specificity of 
TS1M17 siRNA. To provide insights into the possible mechanism of action of TS1M17 
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siRNA, levels of ErbB2 and TS mRNA in SKBR3 cells were verified. Inhibition of 
protein expression can be accomplished by post-trancriptional changes to cellular RNA, 
translational repression or by post-translational modifications. For the latter two 
mechanisms, levels of cellular mRNA would remain intact. To confirm preliminary 
results observed by Northern blot analyses, I subsequently performed an RT-PCR 
analysis. As seen in figure 9, levels of both ErbB2 and TS mRNA decreased significantly 
after treatment with TS1M17 siRNA. Given that the proposed mechanism of gene 
silencing through RNA interference is cleavage of target mRNA, this finding provides 
strong evidence that the expression of ErbB2 and TS protein are both inhibited by 
TS1M17 siRNA through the process of RNA interference. It should be noted that further 
studies looking at quantitative expression of mRNA by Northern blot analysis will show 
comparative data between untreated and treated cells and will be conducted in the future. 
However, taken together, these data provide evidence that TS1M17 siRNA, successfully 
and specifically induces RNAi of two different proteins in SKBR3 cells.  
 
An extensive series of studies have shown that activation of ErbB2 and other members of 
the ErbB family of RTKs results in cell signaling with activation of downstream effector 
pathways. These signaling cascades are responsible for the cellular processes that 
promote cancer cell growth and proliferation, as seen in figure 4. Although the signaling 
networks that are activated subsequent to receptor dimerization and intracellular kinase 
phosphorylation are complex, two important and distinct pathways involved in ErbB 
family signal transduction have been well-defined in the proliferation of tumor cells. 
These are the MAPK/Ras and PI(3)K-induced Akt pathways. It has been shown that 
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inhibition of ErbB2, with agents such as monoclonal antibodies and TKIs, affects cellular 
proliferation through inhibition of these two mentioned pathways. Reports show that this 
inhibition may generate cell cycle arrest and/or induce apoptosis in in vitro breast and 
colon cancer cells (44). Therefore, the termination of these signaling pathways is an 
important component to successful anticancer therapy (74). Unlike monoclonal 
antibodies and TKIs which inhibit protein signaling by preventing receptor 
phosphorylation, siRNAs exert their effects directly at the mRNA level. Prior to the 
present research, no studies had analyzed the effects of ErbB2-specific siRNA on the 
level of phosphorylated ErbB2 receptor protein. I therefore set out to confirm that 
TS1M17 siRNA affects the signaling cascades that are implicated in the effective 
development of anti-ErbB2 drugs. To perform this task, levels of phosphorylated ErbB-2 
protein, which is the initiating event that leads to downstream signaling, were analyzed. 
As seen in figure 10, both unphosphorylated and phosphorylated forms of the ErbB2 
receptor in SKBR3 cells were markedly decreased. In fact, after treatment with TS1M17 
siRNA, levels of active ErbB2 protein were decreased to <5% of baseline value in 
SKBR3 cells after 72 hrs.  
 
Given the finding that TS1M17 siRNA effectively inhibited expression of phosphorylated 
ErbB2 protein, I analyzed other downstream effects of the ErbB2 signaling pathway. One 
concern in this study was the limited duration of effect of TS1M17 siRNA on both active 
and inactive ErbB2 protein in SKBR3 cells. I verified that 72 hr inhibition of 
phosphorylated ErbB2 protein was sufficient to initiate downstream signaling effects on 
the MAPK/Ras pathway. As seen in figure 10, despite the limited time course, a 
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concentration of 10 nM of TS1M17 siRNA was significant enough to inhibit levels of 
phosphorylated MAPK by 44%. These findings suggest that the MAPK pathway was 
affected by TS1M17 siRNA treatment. Given this observation, other downstream effector 
proteins were analyzed by Western blot. Cell cycle modulators, such as p21Cip, p27Kip and 
cyclin D1 have been linked to ErbB2 activation (74). Studies have shown that increased 
expression of ErbB2 receptor in breast cancer cells results in increased turnover of p27 as 
well as increased levels of cyclin D1 and p21. These downstream effects have also been 
implicated as a mechanism for cancer growth and proliferation. We observed that 
treatment of SKBR3 cells with TS1M17 siRNA resulted in 7.3-fold higher levels of p27 
protein than baseline and control cells (Figure 10).  In addition, levels of cyclin D1 and 
p21, which have both been shown to decrease after treatment with ErbB2 inhibitors, were 
inhibited by 87% and 70%, respectively. Sato et al. has linked the expression of the 
inhibitor of apoptosis protein (IAP), survivin, with ErbB2 expression in breast cancer 
cells (72). Survivin levels also decreased by 85% in cells treated with 10 nM of TSM17 
siRNA. The inhibition of these proteins could be attributed to three mechanisms. These 
are direct effects of TS1M17 siRNA on: (1) MAPK/Ras signaling, (2) up-regulation of 
p27, and (3) other signaling pathways that were not analyzed, such as the PI(3)K/Akt 
pathway (Figure 4). Studies have shown that the expression of survivin in breast cancer 
cells is clearly regulated by the PI(3)K/Akt pathway. Further studies will focus on the 
effects of TS1M17 siRNA on this specific signaling cascade. Given that control siRNAs 
(TS1 Mismatch and GL2) did not induce change in baseline levels of any downstream 
protein in SKBR3 cells, I concluded that the process of RNAi itself did not cause the 
noted changes. The effect of RNAi on downstream signaling was previously shown by 
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Reagan-Shaw and colleagues (75). In these studies, an siRNA targeting the mRNA 
encoding the PI(3)K protein was designed and shown to decrease cell cycle proteins and 
induce apoptosis in breast cancer cells. Accumulation of p27 and inhibition of cyclin D1 
was also seen after transfection. These studies suggest that siRNAs can inhibit 
downstream signaling at the initiating event of cytoplasmic receptor phosphorylation. 
Although not directly implicated in these pathways, it is conceivable that TS inhibition 
may also have played a role in our experimental results. Future studies will investigate 
the effect of ErbB2- and TS-specific siRNAs on downstream signaling molecules. 
However, past studies along with the data presented herein suggest that inhibition of 
ErbB2 phosphorylation by TS1M17 siRNA led to the downstream signaling changes. 
 
Our study also set out to investigate the potential benefit of targeting two separate and 
distinct pathways involved in cancer growth and proliferation over inhibiting either target 
alone. The development of targeted cancer drugs has evolved over recent years. Initially, 
the excitement over designing molecules that specifically targeted one protein involved in 
oncogenesis, led to the development of an array of antibodies and TKIs. Although these 
molecules provide enhanced specificity in terms of targeting, they have not shown 
especially significant clinical activity as single therapeutic agents. For example, drugs 
targeting ErbB1 such as the monoclonal antibody, cetuximab, and the small molecule 
TKI, gefitinib, have shown limited response as monotherapy in patients with ErbB1 
positive colon cancers. In recent studies, they have generated only a 10% response rate if 
given without another chemotherapeutic drug (63,76,77). One reason for the limited 
efficacy of these molecular targeted therapies is that there is tremendous redundancy in 
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growth factor signaling pathways in cancer cells that allows for their continued growth 
and proliferation. These targets are ultimately affected by a variety of pathways involved 
in signal transduction that lead to neoplastic disease. One example of the intricate 
networking of signaling pathways is seen in the ErbB family. Therefore, blocking only 
one of these pathways still allows the cell to act through other cellular signaling pathways 
and escape death. Inhibition of multiple targets would potentially prevent this 
phenomenon and induce higher rates of response in cancers such as colorectal, breast, 
and lung (49,78). Clinical trials have begun testing drugs that simultaneously inhibit 
multiple pathways in cancer progression, such as the TKIs ZD6474 and imatinib (Table 
1). Our study also provides data to support targeting of two proteins involved in cancer 
cell growth and proliferation, which may provide enhanced cellular toxicity than 
targeting either protein alone. As seen in figure 11, TS1M17 siRNA inhibits the 
expression of both ErbB2 and TS proteins, and thus has greater growth inhibitory effects 
than SKBR3 cells treated with ErbB2-specific (B2450) or TS-specific (TS7) siRNAs. It 
was shown that both ErbB2- and TS-specific siRNAs inhibit proliferation of SKBR3 cells 
by 51 and 30%, respectively. In contrast, incubation with TS1M17 siRNA resulted in 
nearly 80% growth inhibition. These findings suggest significant suppression on SKBR3 
cell proliferation with an IC50 value of 0.65 nM, which is 154-fold more potent than the 
cytotoxic effects of either ErbB2- or TS-specific siRNAs. Although enhanced cytotoxic 
effects were seen with TS1M17 siRNA treatment, protein analysis also showed that 
TS1M17 siRNA had greater inhibitory effects on ErbB2 protein expression than the 
ErbB-2 specific siRNA, B2450 (Figure 8A). This finding may suggest that the enhanced 
therapeutic effect may be secondary to enhanced inhibitory effects on ErbB2 protein 
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expression rather than the additional inhibitory effects on TS protein expression. Further 
work will analyze ErbB2-specific siRNAs that have improved ErbB2 protein inhibitory 
effects and determine their subsequent effect on cellular proliferation. However, these 
preliminary findings still provide validity to the potential use of multi-targeted siRNAs as 
single agents in the treatment of human malignancies. Given these findings, future studies 
will also focus on developing combination therapies and analyzing possible enhanced 
growth inihibition when multi-targeted siRNAs are used in conjunction with other ErbB2 
and TS inhibitor compounds. With these future studies, we will analyze the potential 
therapeutic application of TS1M17 siRNA in combination therapy for cancer treatment. 
 
The use of a multi-targeted siRNA in combination with other chemotherapeutic agents 
would broaden the therapeutic potential of TS1M17 siRNA. One of the major obstacles 
of cancer chemotherapy is the development of cellular drug resistance. Previous studies 
have shown that exposure to TS-inhibiting compounds results in acute induction of TS 
expression (13). This process has been implicated in the development of cellular drug 
resistance to TS inhibitors. The autoregulation of TS mRNA by its own protein end 
product mediates this process (Figure 2). Schmitz et al. showed that TS-specific siRNAs 
prevented the induction of TS protein in the human colon cancer RKO cell line following 
incubation with TS-inhibitors (38). In addition, they showed that RKO cells 
overexpressing TS enzyme, and therefore chronically resistant to TS inhibiting 
compounds, regained sensitivity to these drugs upon introduction of the TS-specific 
siRNA. Thus, siRNAs may provide a novel approach to circumvent both acquired and 
innate resistance. In this study, the combination of inhibition on ErbB2 and TS 
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expression with a single siRNA molecule may provide enhanced cytotoxicity in ErbB2 
overexpressing cells (Figure 11). Further studies need to be conducted by combining 
TS1M17 siRNA with TS inhibitor compounds, such as 5-FU and raltitrexed, to determine 
whether inhibition of two key cellular signaling pathways can lead to enhanced 
chemosensitivity to tradiational cytotoxic chemotherapy.  
 
The development of targeted drugs has led to a large selection of agents targeting specific 
intracellular pathways. Each of these key cellular signaling pathways is generally altered 
or upregulated in a limited variety of neoplastic cells, narrowing the therapeutic range of 
these target-specific drugs to a few types of cancers. For example, the use of trastuzumab 
is mainly restricted to treatment of ErbB2-positive human breast cancers. This is in 
contrast to the wide therapeutic range of traditional cytotoxic drugs such as 5-FU and 
paclitaxel which have been successfully used in the therapeutic regimens of colorectal, 
breast, and lung cancers. Development of novel multi-targeted drugs has also mostly been 
limited to agents that inhibit multiple pathways altered in specific tumor types, such as 
EGFR, ErbB2 and bcr-abl. Therefore, developing a multi-targeted drug that incorporates 
both targeted and cytotoxic effects could be beneficial for several important reasons. 
First, such an approach would broaden the clinical range of use to multiple tumor types. 
Second, this strategy could possibly reduce the side-effect profiles of cytotoxic agents. 
Current studies are being conducted that combine multi-targeted agents that have both 
target-specific and cytotoxic components (79). As discussed, TS is an important target for 
traditional chemotherapy agents and its inhibition, with drugs such as 5-FU, has been 
successful in the treatment of colorectal, breast, lung, and GI cancers (4). In this study, 
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the inhibition of a selective target (ErbB2) and an enzyme involved in multiple critical 
pathways of human cells (TS) in one molecule was accomplished. In order to test the 
range of efficacy of the multi-targeted siRNA, cytotoxic experiments were conducted in a 
non-ErbB2 receptor expressing human cancer cell line. Previous studies have shown that 
MCF-7, a human breast cancer cell, expresses extremely low base-line levels of ErbB2 
protein. In fact, some have characterized MCF-7 cells as non-ErbB2 expressing (68,73). 
Previous studies from our lab also showed that ErbB2 protein levels were at times 
undetectable at base-line in MCF-7 cells (data not shown). The effect of TS1M17 siRNA 
on the growth of MCF-7 cells was determined, with the knowledge that these cells are not 
dependent on ErbB2 protein for proliferation. As seen in figure 11, the observed effect of 
TS1M17 siRNA was equal to that of a TS-specific (TS7) siRNA. This finding suggests 
that the effect on cell growth was mostly secondary to TS protein inhibition. Targeting 
two separate pathways with TS1M17 siRNA did not seem to produce an enhanced effect 
than targeting one protein alone, but the low-expression of ErbB2 in MCF-7 cells might 
explain this finding. Given that this cell line does not express any ErbB2 receptor, there 
would be no target ErbB2 mRNA for TS1M17 siRNA to inhibit and the siRNA would 
behave as a TS-specific siRNA, as seen in our results. This is supported by the finding 
that the ErbB2-specific siRNA had absolutely no effect on MCF-7 cellular proliferation. 
Previous drug studies also showed that the ErbB2 monoclonal antibody, trastuzumab, had 
absolutely no effect on MCF-7 cellular proliferation (data not shown). These studies 
suggest that in order to see an enhanced effect of TS1M17 siRNA when compared to 
drugs inhibiting either target alone, a cell system that expresses a minimum amount of 
both proteins may be needed. Further studies with other cell lines will need to be 
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conducted to evaluate the range of cancers that this type of molecule effects, particularly 
when compared to more selective agents.  
 
Despite the promising effects of TS1M17 siRNA, studies remain to be done in order to 
elucidate the precise mechanisms of cell inhibition of this multi-targeted siRNA. This 
study shows that TS1M17 siRNA potently inhibits SKBR3 cell proliferation (Figure 11). 
There are two possible mechanisms of inhibiting cell proliferation. These are through 
cytotoxic (apoptosis/necrosis) or cytostatic (cell-cycle arrest) effects of the siRNA on cell 
growth. As seen in figure 10, TS1M17 siRNA had downstream signaling effects on the 
cell-cycle modulators p27 and cyclin D1. These results have been previously reported 
with inhibition of ErbB2 and indicate treatment with TS1M17 siRNA resulted in cell 
cycle arrest (71). However, studies also showed increased inhibition on survivin 
expression after treatment with TS1M17 siRNA, which would suggest induction of 
apoptosis. Some have implicated higher concentrations of drug induce apoptosis, while 
inhibition of ErbB2 phosphorylation at low doses induces G0-G1 phase cycle arrest (44). 
Although these data are applicable to our study, the effect of TS inhibition also plays a 
role in cytotoxicity. Previous studies have demonstrated that TS regulates p53 expression 
by binding directly to a sequence in the coding region of p53 mRNA and represses 
translation (80). Further evidence has shown that inhibition of TS mRNA results in a 
rapid rise in p53 protein levels (24). The p53 tumor suppressor protein plays an essential 
role in preserving the integrity of the genome and for maintaining cell-cycle progression. 
Its expression has been associated with cell-cycle arrest, which allows the cell time to 
repair DNA damage. Levels of p53 have been shown to acutely increase in malignant 
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cells after exposure to chemotherapeutic agents that exert their effects through DNA 
damage. Studies have also shown that the synthesis of p53 is regulated by direct binding 
of TS protein to p53 mRNA (80). Since p53 expression seems to be partly controlled by 
the cellular levels of TS protein, siRNAs targeting TS mRNA may inhibit expression of 
TS protein allowing restoration of p53 levels in cells, and thereby inducing cell-cycle 
arrest. It would also facilitate the apoptotic response seen at high dose concentrations of 
ErbB2 inhibitors. Therefore, future studies using flow cytometry as well as analyzing 
markers of apoptosis, may elucidate the precise mechanism of decreased cell proliferation 
after treatment with TS1M17 siRNA. In addition, analyzing cellular levels of p53 in 
TSM17 siRNA treated cells would verify secondary effects of TS protein inhibition.  
 
The data presented herein provides encouraging results as to the potential therapeutic 
benefit of multi-targeted siRNAs. To continue the development of multi-targeted siRNAs 
as an anticancer agent, the cytotoxic effects of TS1M17 siRNA must be replicated in an 
in vivo model system. Current work is being conducted in harnessing siRNAs for 
systemic use. Attempts to advance the use of siRNA as therapeutic agents are limited by 
several different factors. The first limitation is, because of their negative charge and 
nuclease susceptibility, siRNAs are difficult to deliver and transport into tumor cells. As 
such, siRNAs must be encapsulated in cationic molecules in order to have successful 
uptake into cells. Coupling of siRNAs with a cationic lipid molecule has been difficult in 
in vivo models secondary to toxicity profiles of the cationic molecules. Several strategies 
have been developed to overcome this limitation. One such approach by Urban-Klein et 
al. was to complex siRNA with polyethylenimine (PEI) (81). They observed a 40% 
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reduction in target mRNA levels with tumor growth inhibition following systemic 
application in mice. Another approach is the use of nanoparticles to encapsulate siRNA 
duplexes and permit systemic transport to tumor cells while evading nuclease 
degradation. Schiffelers et al. showed tumor-selective uptake, siRNA sequence 
inhibition, and tumor growth inhibition with intravenous administration of ligand-
directed nanoparticles containing VEGFR2-specific siRNA into tumor bearing mice (82). 
Given the potential of nanotechnology for cancer therapy, studies from our own lab are 
currently analyzing the delivery of an optimized TS-targeted siRNA to colon cancer cell 
tumors in nude mice with nanoparticles. The second limitation relates to the potential 
non-specific effects of non-homologous targeting. These effects could prove to be 
problematic in a clinical setting. Recently, Grimm et al. showed that transfection of mice 
carrying small-hairpin RNAs suffered from hepatoxicity. These findings were felt to be 
secondary to competition between endogenous siRNAs and foreign siRNAs for cellular 
transport (83). Therefore, the in vivo and clinical systemic use of siRNAs must wait until 
further research is done in elucidating and harnessing the mechanisms of RNAi.  
 
In the present report, I have developed a novel approach of using a single siRNA 
molecule to target multiple pathways involved in cancer proliferation. The use of RNAi 
to inhibit two proteins is an innovative approach to cancer drug development. This thesis 
has shown that a multi-targeted siRNA directed at both ErbB2 and TS mRNA 
specifically and potently inhibited the expression of ErbB2 and TS protein in human 
breast cancer SKBR3 cells via the process of RNAi. This approach showed that inhibition 
of both ErbB2 and TS protein may result in enhanced cytotoxic effect than inhibition of 
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either protein alone. In addition, downstream signaling pathways were shown to be 
effected by treatment of low concentrations of multi-targeted siRNA. The use of multi-
targeted drugs has become a valuable tool in cancer treatment secondary to its therapeutic 
benefits. These results, taken together, highlight the therapeutic promise of multi-targeted 
siRNAs as a strategy to be used as monotherapy or in combination with other 
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